Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Organogenesis Holdings (ORGO) over the last 10 years, with Q3 2025 value amounting to $11.9 million.

  • Organogenesis Holdings' Change in Accured Expenses rose 62381.58% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 5921.52%. This contributed to the annual value of $9.2 million for FY2024, which is 19203.31% up from last year.
  • Organogenesis Holdings' Change in Accured Expenses amounted to $11.9 million in Q3 2025, which was up 62381.58% from -$5.9 million recorded in Q2 2025.
  • Organogenesis Holdings' 5-year Change in Accured Expenses high stood at $11.9 million for Q3 2025, and its period low was -$8.0 million during Q1 2025.
  • Its 5-year average for Change in Accured Expenses is $413842.1, with a median of $1.2 million in 2021.
  • As far as peak fluctuations go, Organogenesis Holdings' Change in Accured Expenses crashed by 40084.97% in 2022, and later surged by 62381.58% in 2025.
  • Organogenesis Holdings' Change in Accured Expenses (Quarter) stood at $2.6 million in 2021, then tumbled by 400.85% to -$7.8 million in 2022, then soared by 35.28% to -$5.0 million in 2023, then surged by 165.11% to $3.3 million in 2024, then soared by 263.89% to $11.9 million in 2025.
  • Its last three reported values are $11.9 million in Q3 2025, -$5.9 million for Q2 2025, and -$8.0 million during Q1 2025.